Synonyms: Arlansa® | SCH 900518 | SCH-900518 | SCH900518
narlaprevir is an approved drug (Russia (2016))
Compound class:
Synthetic organic
Comment: Narlaprevir (SCH90051) is an oral HCV NS3 serine protease inhibitor [1,3]. It is structurally related to boceprevir. Narlaprevir forms a reversible covalent bond with the protease's active-site serine. It has also been reported to inhibit SARS-CoV-2 coronavirus main cysteine protease (3CLpro or Mpro) in vitro [2].
|
|
References |
1. Arasappan A, Bennett F, Bogen SL, Venkatraman S, Blackman M, Chen KX, Hendrata S, Huang Y, Huelgas RM, Nair L et al.. (2010)
Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor. ACS Med Chem Lett, 1 (2): 64-9. [PMID:24900178] |
2. Manandhar A, Blass BE, Colussi DJ, Almi I, Abou-Gharbia M, Klein ML, Elokely KM. (2021)
Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening. J Chem Inf Model, 61 (2): 1020-1032. [PMID:33538596] |
3. Tong X, Arasappan A, Bennett F, Chase R, Feld B, Guo Z, Hart A, Madison V, Malcolm B, Pichardo J et al.. (2010)
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. Antimicrob Agents Chemother, 54 (6): 2365-70. [PMID:20308381] |